Humana Inc. (NYSE:HUM) Stock Position Decreased by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 26.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,435 shares of the insurance provider’s stock after selling 527 shares during the quarter. Snowden Capital Advisors LLC’s holdings in Humana were worth $365,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Siemens Fonds Invest GmbH boosted its stake in shares of Humana by 23.7% during the 4th quarter. Siemens Fonds Invest GmbH now owns 7,567 shares of the insurance provider’s stock worth $1,920,000 after acquiring an additional 1,448 shares in the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Humana by 11.9% during the 4th quarter. Rafferty Asset Management LLC now owns 13,659 shares of the insurance provider’s stock worth $3,465,000 after acquiring an additional 1,448 shares in the last quarter. Raiffeisen Bank International AG bought a new stake in shares of Humana during the 4th quarter worth $1,954,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Humana during the 4th quarter worth $78,000. Finally, Redwood Grove Capital LLC bought a new stake in shares of Humana during the 4th quarter worth $14,099,000. 92.38% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Guggenheim assumed coverage on Humana in a research note on Wednesday, April 9th. They set a “buy” rating and a $326.00 price objective for the company. Barclays raised their target price on Humana from $270.00 to $322.00 and gave the stock an “equal weight” rating in a research report on Friday, April 11th. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. Morgan Stanley decreased their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, Truist Financial decreased their target price on Humana from $325.00 to $305.00 and set a “hold” rating for the company in a research report on Monday, May 12th. Seventeen analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $286.81.

Humana Price Performance

Shares of NYSE:HUM opened at $246.02 on Thursday. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46. The business has a fifty day simple moving average of $262.84 and a 200 day simple moving average of $269.22. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $29.69 billion, a price-to-earnings ratio of 24.73, a P/E/G ratio of 2.05 and a beta of 0.49.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. During the same period last year, the company earned $7.23 earnings per share. The business’s revenue was up 8.4% compared to the same quarter last year. As a group, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.44%. Humana’s payout ratio is presently 25.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.